LexDanaLexDanabeta
Inventor

Gang Liu

Inventor
Gurnee, IL, US

Overview

76→
Patents
1998–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 76 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds41%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
A61KPreparations for medical, dental or toiletry purposes16%
C07CAcyclic or carbocyclic compounds5%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
C07BGeneral methods of organic chemistry2%
C07HSugars1%
C07KPeptides1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
G02BOptical elements, systems or apparatus1%
PatentTitleYear
11,108,466Electronic equipment202110,829,484Compounds and methods for kinase modulation, and indications therefor202010,766,892GLS1 inhibitors for treating disease202010,662,214Compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof202010,428,057Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease201910,370,352Cyclobutyl-imidazolidinone compounds201910,344,025GLS1 inhibitors for treating disease201910,287,266Compounds and compositions for inhibiting the activity of SHP2201910,150,753Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide201810,112,9313-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH201810,093,664Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease20189,938,261Heterocyclic compounds and methods of use thereof20189,809,588'GLS1 inhibitors for treating disease'20179,725,465'Biaryl acetamide compounds and methods of use thereof'20179,688,672'3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH'20179,662,353'Iron-based montmorillonite medicament for treating hyperphosphatemia and iron-deficiency anemia, and preparation method therefor'20179,452,167'Heterocyclic compounds and methods of use thereof'20169,434,719'3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH'20169,308,207'JAK kinase modulating compounds and methods of use thereof'20169,296,722'Azolyl urea compounds and methods of use thereof'20169,115,120'Heterocyclic modulators of HIF activity for treatment of disease'20159,085,605'Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate'20158,957,068'3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH'20158,952,058'Heterocyclic compounds and methods of use thereof'20158,927,711'JAK kinase modulating compounds and methods of use thereof'20158,557,830'RAF kinase modulators and methods of use'20138,557,828'Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme'20138,470,763'Alpha-amino-N-substituted amides, pharmaceutical composition containing them and uses thereof'20138,440,674'Substituted pyrimidine compounds as RAF inhibitors and methods of use'20138,349,883'Hydroxamate-based inhibitors of deacetylases B'20138,349,851'JAK kinase modulating compounds and methods of use thereof'20138,338,440'Inhibitors of IAP'20128,207,183'Inhibitors of IAP'20128,076,344'Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme'20117,989,461'Substituted quinazolinamine compounds for the treatment of cancer'20117,943,652'Hydroxamate-based inhibitors of deacetylases B'20117,888,374'Inhibitors of c-jun N-terminal kinases'20117,858,785'Aminopyrimidine compounds and methods of use'20107,786,132'Aminopyrimidine compounds and methods of use'20107,419,975'Organic compounds'20087,365,093'Endothelin antagonists'20087,208,517'Endothelin antagonists'20077,196,104'Thiazolyl urea compounds and methods of uses'20077,169,797'Protein-tyrosine phosphatase inhibitors and uses thereof'20077,119,205'Thienopyridones as AMPK activators for the treatment of diabetes and obesity'20067,115,767'Tetraline derivatives as ghrelin receptor modulators'2006RE039197'Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds'20066,972,340'Selective protein tyrosine phosphatatase inhibitors'20056,946,481'Endothelin antagonists'20056,878,700'Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds'20056,720,339'Certain fused pyrrolecarboxamides; a new class of GABA brain receptor ligands'20046,646,124'Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands'20036,645,990'Thiazolyl urea compounds and methods of uses'20036,627,767'Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors'20036,515,140'Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands'20036,472,545'Protein tyrosine phosphatase inhibitors'20026,462,194'Endothelin antagonists'20026,448,246'Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands'20026,423,711'Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands'20026,399,604'Substituted 4-OXO-napthyridine-3-carboxamides; GABA brain receptor ligands'20026,380,209'4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands'20026,380,241'Treatment of diseases using endothelin antagonists'20026,353,109'Certain fused pyrrolecarboxamides; a new class of GABA brain receptor'20026,297,256'Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands'20016,228,868'Oxazoline antiproliferative agents'20016,211,365'Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands'20016,204,293'Inhibitors of protein isoprenyl transferases'20016,166,203'Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands'20006,162,927'Endothelin antagonists'20006,143,760'Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands'20006,110,922'Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds'20006,103,903'4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands'20006,096,887'Certain fused pyrrolecarboxamides; a new class of GABA brain receptor ligands'20006,080,873'Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands'20005,804,686'fused pyrrolecarboxamides; a new class of GABA brain receptor ligands'19985,723,462'Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands'1998

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1998–2004Patents assigned to NEUROGEN CORP (17)· patent assignee history
2000–2011Patents assigned to ABBOTT LAB (17)· patent assignee history
2000–2008Based in Gurnee, IL, US· patent location history
2000–2003Based in Agoura, CA, US· patent location history
2003–2013Based in Oak Park, CA, US· patent location history
2008–2019Patents assigned to NOVARTIS AG (10)· patent assignee history
2008–2019Based in Waltham, MA, US· patent location history
2011–2016Patents assigned to LIU GANG (13)· patent assignee history
2011–2020Based in San Diego, CA, US· patent location history
2013–2018Patents assigned to AMBIT BIOSCIENCES CORP (8)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ABBOTT LAB172000–2011
NEUROGEN CORP171998–2004
LIU GANGself132011–2016
NOVARTIS AG102008–2019
AMBIT BIOSCIENCES CORP82013–2018
Locations
LocationPatentsSpan
Gurnee, Illinois, US162000–2008
San Diego, California, US112011–2020
Agoura, California, US102000–2003
Oak Park, California, US92003–2013
Waltham, Massachusetts, US82008–2019